Organogenesis (ORGO) Expected to Announce Earnings on Thursday

Organogenesis (NASDAQ:ORGO - Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $109.60 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Organogenesis Trading Down 4.7 %

Organogenesis stock traded down $0.16 during midday trading on Friday, reaching $3.22. 96,845 shares of the stock traded hands, compared to its average volume of 452,388. The company has a 50-day simple moving average of $3.38 and a two-hundred day simple moving average of $3.20. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a market cap of $405.10 million, a PE ratio of -53.67 and a beta of 1.77. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.57.

Insider Transactions at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of the business's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the sale, the chief executive officer now directly owns 3,400,778 shares in the company, valued at approximately $12,412,839.70. The trade was a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 278,116 shares of company stock valued at $991,190. Corporate insiders own 36.90% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.